Related Experiment Video

Updated: May 18, 2026

A Modified Inflammatory Pain Model to Study the Analgesic Effect in Mice
06:54

A Modified Inflammatory Pain Model to Study the Analgesic Effect in Mice

Published on: November 15, 2024

Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies

Rachel Huelin1, Tiffany Pokora, Talia S Foster

  • 1United BioSource Corporation, Lexington, MA 02420, USA. rachel.huelin@unitedbiosource.com

Expert Review of Pharmacoeconomics & Outcomes Research
|September 14, 2012
PubMed

Insights

Celecoxib offers a favorable cost-effectiveness profile for managing osteoarthritis and rheumatoid arthritis, leading to lower direct medical costs compared to nonselective NSAIDs.

Area of Science:

  • Rheumatology
  • Health Economics

Background:

  • Osteoarthritis (OA) and rheumatoid arthritis (RA) impose significant clinical and economic burdens.
  • Treating these disabling conditions strains healthcare systems due to high medical costs.

Purpose of the Study:

  • To systematically review the economic impact of celecoxib in patients with OA and RA.
  • To evaluate the cost-effectiveness and direct medical costs associated with celecoxib use.

Main Methods:

  • Systematic review of 24 studies examining economic outcomes.
  • Analysis included cost-effectiveness studies comparing celecoxib with nonselective NSAIDs (non-steroidal anti-inflammatory drugs).
  • Consideration of studies from diverse geographical regions, including developing areas.

Main Results:

  • Economic models generally indicated favorable cost-effectiveness for celecoxib versus nonselective NSAIDs.
  • Celecoxib demonstrated lower direct medical costs compared to alternative treatments.
  • Six studies specifically evaluated economic outcomes in developing regions.

Conclusions:

  • Celecoxib presents a cost-effective treatment option for patients with OA and RA.
  • The use of celecoxib is associated with reduced direct healthcare expenditures.
  • Findings support the economic viability of celecoxib in managing these rheumatic conditions.

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...